PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Regulatory Review

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to Champignon’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company. “With the recent growth and interest in our industry, ensuring our disclosure obligations are satisfied is at the forefront of our attention.  Ensuring fulsome and timely disclosure is vital to the success of our Company, and development of our industry with the investing public,” Champignon CEO Dr. Roger McIntyre stated in the news release. “We look forward to working with staff of the British Columbia Securities Commission to complete their review, and are hopeful that trading will resume as soon as possible.”

To view the full press release, visit http://ibn.fm/JSXzm

About Champignon Brands Inc.

Champignon Brands (CSE: SHRM) is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

420 with CNW – Survey Shows Link Between Marijuana Legalization and Reduced Teen Marijuana Abuse Admissions

Marijuana legalization is one of the most divisive topics of the decade. While proponents swear by its medical abilities and say that taxes from cannabis sales can be used to address various social issues, those against argue that it is a gateway drug and that legalizing it will make it more accessible to children and teenagers. In fact, a survey by Gallup found that 83% of opponents to legalization believe it would make marijuana more accessible to the youth. However, a survey of cannabis use disorders carried out in Colorado and Washington found this to be wholly untrue.

The survey was led by researchers from Temple University and published in the journal Drug and Alcohol Dependence. The study concluded that after recreational marijuana was legalized, “the rate of adolescent treatment admissions for marijuana use declined significantly, with the mean rate falling nearly in half between 2009 and 2017. The decline in admissions rate was greater in Colorado and Washington compared to other states where recreational marijuana is not legal.” This is despite the fact that for more than 70% of minors admitted for treatment in Colorado, marijuana is their drug of choice.

“While we are encouraged that rates of new treatment admissions for marijuana use among adolescents exhibited a general decline in the studies we examined, it is unclear whether these findings reflect trends in the prevalence of CUD (cannabis use disorder) or, rather, changes in treatment-seeking behavior due to changing perceptions of risk and public attitudes towards marijuana use,” the authors of the study caution.

They say that the worst-case scenario is that the need for treatment still exists but isn’t being met for some reason despite youth use stagnating or even increasing. “It may be the case that admission rates are falling because an increasing proportion of adolescents with CUD are not entering treatment.”

This study adds to a large body of research on the effects of legalizing marijuana on the country’s youth. A study by the Colorado Division of Criminal Justice to determine the effects of legalizing marijuana on the youth concluded that Colorado is not experiencing an increase in youth usage of marijuana. “The youth marijuana rate reported for the 2017-2018 school year (9.1%) was the lowest it’s been since 2007-2008, and the proportion of students trying marijuana before age 13 went down from 9.2% in 2015 to 6.5% in 2017.”

Analysts say these research findings give sector players like Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) to push for the easing of federal restrictions on conducting marijuana research so that more reliable information is available about this versatile plant.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

PsychedelicNewsBreaks – Champignon Brands Inc.’s (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Dr. McIntyre / CRTCE Published in Two Peer Reviewed Study Journals

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (“MDD”) while demonstrating rapid onset efficacy and safety of its treatment processes. To this accord, the Company today announced that its Chief Executive Officer, Dr. Roger McIntyre, and the Canadian Rapid Treatment Centre of Excellence (the “CRTCE”) have been recently published in two peer reviewed study journals (the “Peer Reviewed Studies”) focusing on ketamine’s safety, tolerability and effectiveness. “The publications of data as it relates to ketamine treatment at the CRTCE continues to demonstrate the rapid and robust efficacy of ketamine in persons with depression and related disorders,” Dr. McIntyre, Champignon’s CEO, said in the news release. “Our data, for the first time in the field of psychiatry, shows that ketamine can improve a person’s ability to function in their role and return to work within a few weeks. The significant efficacy of ketamine at our centre is also matched by stable side-effect profiles, as well as the acceptability of ketamine in people who are benefitting from this novel treatment.”

To view the full press release, visit http://ibn.fm/CwdEl

About Champignon Brands Inc.

Champignon Brands (CSE: SHRM) is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

420 with CNW – Missouri Medical Marijuana Growers Face Additional Roadblock Before Planting Crops

At the moment, 33 states have legalized medical cannabis and 11 states plus Washington D.C. have taken things further and legalized recreational use. States with relatively successful legal marijuana programs like California and Colorado have surpassed $1 billion in cannabis tax revenue, and numerous advocates in other states are pushing for legalization. However, the industry is still immature, processes aren’t streamlined across the board and everyone from cultivators to retailers is subject to lengthy and time-consuming verification processes.

Marijuana business owners in Missouri, for instance, already face a lengthy verification process, and they say they have been caught off guard by an additional hurdle imposed by the Missouri Department of Health and Senior Services, which is in charge of overseeing the industry. There are 338 licensed medical marijuana providers, and after being verified by the state, they are now required to go through an additional verification process.

“Once those 338 were chosen by merit, the Department of Health did a verification process where they go through the application with a license holder to prove that everything they put on the application was accurate, correct and conforms to the department’s rules,” says Jack Cardetti, spokesman for MoCannTrade. Once this is completed, there is a final step called a ‘commencement inspection’ before cultivators, manufacturers, and dispensaries can start operating. Inspectors will “come on-site, look at your facility, make sure it has all the security you said it was going to have and make sure that all the promises that were made on the application were followed through on,” says Cardetti.

Only two of 60 cultivators have made it through the process so far near St. Louis. According to Nate Ruby, president of OXG, the verification process “kind of came as a surprise to probably all of us that won licenses.” He has already been verified by the state, and he hopes his commencement inspection is done soon so he can start planting inside his 17,000 square foot greenhouse in Independence. “Hopefully we’ll start growing by July, harvest around October, November, and get the product in our dispensaries.”

Kansas City Cannabis Company hasn’t been verified yet, but Chief Information Officer Nolan Lawrence hopes the final step will be completed soon. However, “that involves a whole lot of paperwork and documentation with investors, owners, and affiliates of the business.”

It isn’t yet clear what sector players like Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) think about the additional steps that their counterparts in Missouri have to go through before getting their operations started.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Provides Corporate Update

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Friday provided a corporate update. Since commencing trading on March 2, 2020, the Company has expanded its initiatives and rapidly executed on such initiatives to position it as a leading publicly traded psychedelic medicine company developing novel rapid onset treatments for depression, post-traumatic stress disorder (“PTSD”), and substance-use disorders (“SUD”) via the clinical delivery of ketamine and ketamine-derivatives. In the update, the Company shared its corporate advancements and achievements over the last quarter, which target key segments in the psychedelics as medicines industry that will complement each other as the sector matures and accelerates. “While the topic of medical psychedelics has recently gained worldwide momentum, I am exceptionally pleased with the strategic approach our team has taken in establishing a differentiated platform with operating treatment clinics in the U.S. and Canada that also facilitate research and development of a wide range of therapeutic and medical applications,” Champignon CEO Dr. Roger McIntyre stated in the news release. “We have made tremendous progress to date and have proven our ability to quickly seize opportunities in this rapidly emerging industry. Looking forward to the second half of 2020, we will continue to work towards entering new markets and delivering new and innovative solutions throughout North America.”

To view the full press release, visit http://cnw.fm/dIfT5

About Champignon Brands Inc.

Champignon Brands (CSE: SHRM) is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1)  access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Pros and Cons of Different CBD Drinks

If you have been paying attention to the cannabis space for the past few years, you must have heard of cannabidiol or CBD, a chemical extracted from cannabis that is taking the world by storm. One of its biggest attractions is that it doesn’t create a psychoactive high, meaning users can use it for its health benefits and stay clear-headed. And it has a ton of medical benefits, with studies finding it effective against a myriad of conditions such as anxiety, chronic pain, and high blood pressure.

There are plenty of ways you can consume cannabis, such as smoking cannabis flower, ingesting it through gummies and other confectioneries, and applying it topically. In fact, CBD gummies were the third most searched for food by Americans in 2018, and CBD-infused drinks are quickly emerging as the next best thing in the CBD/cannabis space. They are accessible, easy to administer, and a lot safer than alcohol and other energy drinks.

CBD coffee, for instance, can be found in many restaurants and coffee shops, and you can buy your own CBD oil and make your own CBD coffee at home. Although coffee helps perk you up and keeps you alert, it can also increase your heart rate and cause headaches and anxiety. CBD has been proven to reduce anxiety and improve circulatory health, making it a perfect counter for coffee’s more unpleasant effects.

Like cannabidiol-infused coffee, CBD water has been around for a while, and it is just as simple to consume. The CBD is infused in the water through nano emulsion technology and it needs no extra preparation once purchased. However, most brands infuse the minimum level of CBD (2-5mg) in the water, so you’ll need a higher dose of CBD water for the health benefits to kick in. Studies suggest at least 15mg of CBD every day. You may also want to avoid buying from supermarkets as the CBD particles will degrade when exposed to light and air on the shelves, thereby making them less effective.

You may also be interested in CBD cocktails, which take unwinding and relaxation to a whole other level. CBD oil’s earthy, plant-like taste makes it a great addition to gin and amaro-based cocktails, and the combination will leave you feeling relaxed and mellowed out. CBD alcohol may also alleviate anxiety and insomnia while eliminating the dreaded hangover. However, there has been little research on CBD cocktails’ particular effect on the body. You will also have to limit your intake as this is alcohol after all, and it is only good in moderation.

As you can see, your options of CBD drinks are increasing by the day, and analysts say sector players like Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRM) (FWB: 496) may be working behind the scenes to increase the options even more.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Federal Financial Regulator Says Marijuana Banking is a Difficult Issue

Despite being federally prohibited, the state-legal marijuana industry has been growing steadily for the past few years. Things haven’t been rosy for the often controversial sector, and the fact that marijuana is illegal at the federal level has made it challenging for businesses to operate. Admittedly, the biggest hurdle that the industry has faced is lack of access to banking.

Fearing legal retaliation from the federal government, most banking institutions avoid marijuana businesses, locking them out of accessing credit or loans and forcing them to operate on a cash-only basis. There have been numerous calls from stakeholders and advocates to rectify this situation, but according to the head of the Federal Deposit Insurance Corporation (“FDIC”), marijuana banking represents the ‘most challenging issue’ she has encountered at the agency.

“At a federal level it is still an illegal substance, and at many state levels, it’s now legal, and it’s legal to frankly bank it at a state level. And so banks find themselves caught between the federal regulatory regime and the state,” says FDIC Chair Jelena McWilliams. While there are hopes that Congress will pass a bill that gives the marijuana sector access to banking services, she tells banks that “there’s so much uncertainty in this space that as a federal regulator, I still have to say it’s illegal to bank marijuana.”

“We know we have banks that are banking marijuana businesses, and you know, we can’t bless them and say ‘go ahead and do it.’ But to the extent you’re doing it because it’s legal in your state, follow FinCEN guidance,” she says, referring to guidance issued for financial services that bank marijuana businesses by the Financial Crimes Enforcement Network (FinCEN) in 2014.

Stakeholders and advocates have been holding out hope that the historic Secure and Fair Enforcement (“SAFE”) Banking Act could still advance in Congress this year Sponsored by Rep. Ed Perlmutter, the bill would protect banks and financial institutions that serviced the marijuana industry from being penalized by federal regulators. The need for cashless transactions has been made even more urgent by the ongoing coronavirus crisis. Not only does having piles of cash around pose a security risk, but it increases the staff’s and customers’ chances of being infected by the virus.

This resulted in the inclusion of language from the SAFE Banking Act into a House-passed coronavirus relief package. It is now waiting for Congressional approval.

Industry watchers believe that sector players like Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) may be wondering about what sort of extreme event will cause the federal government to finally allow banks to serve legal marijuana businesses in nearly all the states in the country.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Engages Toronto-based Dalriada to Advance NCE IP Portfolio

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced its selection of Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. According to the update, Dalriada, a leading contract research organization (“CRO”) in the drug discovery space, will lead Champignon’s new drug discovery programs in the NCE arena and further provide integrated R&D support to accelerate the Company’s existing preclinical assets and ongoing development of proprietary delivery platforms. “It is with great pleasure that we welcome the Dalriada group to Champignon,” Champignon Special Advisor Dr Joseph Gabriele stated in the news release. “Dalriada’s expertise in medicinal chemistry will be a monumental addition to Champignon’s innovative diverse formulation platforms by their expertise in the synthesis of molecules, including existing psychedelics (ketamine, psilocybin and MDMA), as well as novel new psychedelic-like molecules. This synergistic collaboration will differentiate Champignon from other companies in the psychedelic space by boosting our ability to maintain an inhouse infrastructure for the clinical delivery NCEs.”

To view the full press release, visit http://cnw.fm/6KpoK

About Champignon Brands Inc.

Champignon Brands (CSE: SHRM) is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com

905.674.5977

Office
Editor@CanadianCannabisWire.com

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Names New CEO

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human-optimization sciences company with an emphasis on ketamine and psychedelic medicine, recently named Dr. Roger McIntyre as chief executive officer. An article discussing the company reads, “In his new role, Dr. Roger McIntyre brings impressive experience in the ketamine and psychedelic medicine space, a key focus area for Champignon. . . . ‘My overarching aim as chief executive officer is to establish Champignon as the apotheosis of integrated ketamine treatment delivery and the commercialization of our own IP psychedelic-based treatments,’ McIntyre stated in a news release. ‘The clinical infrastructure, complementary asset base and human capital that Champignon has acquired leaves me very confident we will provide life-changing treatments for persons with depression, all the while contemporaneously rewarding our investor base.’”

To view the full article, visit http://cnw.fm/8TrHA

About Champignon Brands Inc.

Champignon Brands is focused on the formulation and manufacturing of novel ketamine, anesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The company is pursuing the development and commercialization of rapid-onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or standalone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Four Ways the Marijuana Industry Can Benefit from the HEROES Act

Experts say we may be facing up to two years of intermittent lockdowns before the coronavirus is finally eradicated, and the economy will take even longer to spring back to pre-pandemic levels. At the moment, most regions in the U.S. are still under lockdown orders, and while this has helped reduce infections, the effect it has had on the economy has been catastrophic.

The cannabis sector was one of the few industries that were deemed essential and allowed to continue operating amidst lockdown orders. However, due to federal prohibition, the industry has been operating at a stark disadvantage. The federal government released emergency relief funds to help small businesses weather the storm, but the state-legal marijuana industry has been denied access to these funds.

To make matters worse, these businesses have been locked out of most banking services. Banking institutions may be subject to federal retaliation if they transact with the state-legal industry, and this has forced marijuana businesses to transact on a cash-only basis. Not only does having lots of cash on hand put you at risk of theft, but it also puts employees, and customers at risk of infection.

The Health and Economic Recovery Omnibus Emergency Solutions (“HEROES) Act, a $3 trillion stimulus package, would help the industry immensely. Although it doesn’t grant the industry access to federal emergency relief funds, it contains language from the industry-lauded Secure and Fair Enforcement (“SAFE) Banking Act, which would give cannabis businesses and their ancillary business partners access to the banking sector.

If it is passed, the HEROES Act would:

  • Allow cannabis businesses to access much needed banking services like loans, credit lines and bank accounts. At the moment, the banking sector treats such businesses like pariahs and with the current health and economic crisis, this has put them at a severe disadvantage. The HEROES Act will allow the banking sector to transact with cannabis businesses without fear of federal retaliation.
  • Additionally, customers will now be able to use credit and debit cards as the Act will allow marijuana businesses to finally use credit card processing services. They will be subject to lower debit card fees as credit companies compete for the new market. It may also aid bottom lines as studies have shown that people are more likely to spend more when using credit cards compared to cash.
  • Consumers will also spend less on fees, specifically ATM fees, which can and will add up if ATM transactions are part of your cannabis purchases. Using debit or credit cards would be more economical in the long run. If firms adapt to a cashless system, they will spend less on security to keep the staff safe from petty theft, and these cost savings can be passed down to the consumers.
  • Finally, and most importantly, it will prevent the spread of the coronavirus. It is a known fact that the virus is still viable after extended stays on surfaces like cash and plastic. In fact, money was never hygienic to begin with, and therein lies the danger of cash-only transactions. Eliminating physical currency from the equation would limit the contact between staff and customers, thereby reducing their chances of contracting and spreading the virus.

The progress of this proposed law will no doubt be monitored closely by cannabis sector players like Round Meadow Holdings Corp. and Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) to see how the lawmakers debate and vote on this bill.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.